Biogen (BIIB) Competitors

Regeneron Pharmaceuticals (NASDAQ:REGN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, community ranking, valuation, earnings and risk.

Do institutionals & insiders believe in REGN or BIIB?

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 7.5% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of Biogen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Do analysts recommend REGN or BIIB?

Regeneron Pharmaceuticals currently has a consensus target price of $1,015.38, suggesting a potential upside of 48.97%. Biogen has a consensus target price of $230.00, suggesting a potential upside of 63.64%. Given Biogen's higher possible upside, analysts plainly believe Biogen is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	1 Sell rating(s)	7 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.65
Biogen	0 Sell rating(s)	16 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.43

Is REGN or BIIB more profitable?

Regeneron Pharmaceuticals has a net margin of 33.61% compared to Biogen's net margin of 16.81%. Regeneron Pharmaceuticals' return on equity of 16.88% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	33.61%	16.88%	13.23%
Biogen	16.81%	14.98%	8.59%

Does the media favor REGN or BIIB?

In the previous week, Regeneron Pharmaceuticals had 35 more articles in the media than Biogen. MarketBeat recorded 63 mentions for Regeneron Pharmaceuticals and 28 mentions for Biogen. Biogen's average media sentiment score of 0.54 beat Regeneron Pharmaceuticals' score of 0.24 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	20 Very Positive mention(s)	6 Positive mention(s)	27 Neutral mention(s)	7 Negative mention(s)	1 Very Negative mention(s)	Neutral
Biogen	10 Very Positive mention(s)	4 Positive mention(s)	12 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, REGN or BIIB?

Regeneron Pharmaceuticals has a beta of 0.1, indicating that its share price is 90% less volatile than the S&P 500. Comparatively, Biogen has a beta of -0.07, indicating that its share price is 107% less volatile than the S&P 500.

Does the MarketBeat Community favor REGN or BIIB?

Biogen received 267 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 71.74% of users gave Biogen an outperform vote while only 66.97% of users gave Regeneron Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Regeneron Pharmaceuticals	Outperform Votes 1543 66.97%	Underperform Votes 761 33.03%
Biogen	Outperform Votes 1810 71.74%	Underperform Votes 713 28.26%

Which has higher earnings and valuation, REGN or BIIB?

Regeneron Pharmaceuticals has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$13.12B	5.71	$3.95B	$40.41	16.87
Biogen	$9.61B	2.13	$1.16B	$11.07	12.70

Summary

Regeneron Pharmaceuticals beats Biogen on 14 of the 19 factors compared between the two stocks.